In 2014, MAPS completed the first double-blind, placebo-controlled study of the therapeutic use of LSD in human beings since the early 1970s.
MAPS is interested in LSD for its potential to help people with a variety of conditions, focusing primarily on the treatment of anxiety associated with life-threatening illness.
Our Phase 2 pilot study in 12 subjects found positive trends in the reduction of anxiety following two LSD-assisted psychotherapy sessions. The study results also indicate that LSD-assisted psychotherapy can be safely administered in these subjects, and justify further research.
home research areas LSD